Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?

Stockley, Robert A and Edgar, Ross G and Starkey, Sian and Turner, Alice M (2018) Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies? Respiratory research, 19 (1). p. 137. ISSN 1465-993X. This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs

[img]
Preview
Text
Health status decline in α-1 antitrypsin.pdf - Published Version
Available under License Creative Commons Attribution.

Download (831kB) | Preview
Official URL: https://respiratory-research.biomedcentral.com/art...

Abstract

BACKGROUND

Trials of disease modifying therapies in Chronic Obstructive Pulmonary Disease (COPD) provide challenges for detecting physiological and patient centred outcomes. The purpose of the current study was to monitor decline in health status in Alpha-1 antitrypsin deficiency (AATD) and determine its' relationship to conventional physiology.

METHODS

Patients recruited to the UK-AATD database with a median follow up of 7 years (IQR 5-10) were studied to determine annual change in St George's Respiratory Questionnaire (SGRQ), FEV, gas transfer and their feasibility of use in future trials.

RESULTS

Annual decline in SGRQ had a wide range, was greater for patients with established COPD and correlated with decline in FEV (p < 0.0001). Total score decline was greater (p < 0.05) for those with accelerated FEV decline (median = 1.07 points/year) compared to those without (median = 0.51). Power calculations indicated effective intervention would not achieve MCID for the SGRQ unless the timeframe was extended for up to 8 years. More than 5000 patients/arm would be required for a statistically significant modest effect over 3 years even in those with rapid FEV decline.

CONCLUSION

Despite AATD being a rapidly declining form of COPD, deterioration in SGRQ was slow consistent with ageing and the chronic nature of disease progression. Power calculations indicate the numbers needed to detect a difference with disease modifying therapies would be prohibitive especially in this rare cause of COPD. These data have important implications for future study design of disease modifying therapies even in COPD not associated with AATD.

Item Type: Article
Additional Information: This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs
Subjects: WF Respiratory system. Respiratory medicine
Divisions: Planned IP Care > Respiratory Medicine
Related URLs:
Depositing User: Miss Emily Johnson
Date Deposited: 21 Nov 2018 16:10
Last Modified: 21 Nov 2018 16:10
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/1783

Actions (login required)

View Item View Item